Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
Clinical trial NCT06345183 · COMPLETED
Trial details
- NCT number
- NCT06345183
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2024-02-19
- Primary completion
- 2024-04-04
- Enrollment
- 327
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.